Publication Date

Fall 2019

Advisor(s) - Committee Chair

Dr. Kevin Williams (Director), Dr. Eric Conte, and Dr. Blairanne Williams

Degree Program

Department of Chemistry

Degree Type

Master of Science


In the 1960s, Rosenberg and his colleagues confirmed the anti-cancer activity of cisplatin. Although cisplatin was capable of killing testicular cancer cells there were also serious side effects. It was necessary to find alternate ways of overcoming side effects, and soon many researchers have discovered novel platinum compounds that show similar reactivity. Recently, replacing one chloride group to a heterocyclic amine group showed significant cytotoxicity with a different binding activity than cisplatin. Previously in our lab, [Pt(Me5dien)(NO3)]+ and [Pt(Et2dien)Cl]+ have been synthesized and reacted with NAcetyl- L-methionine (N-AcMet) and Guanosine 5’-monophosphate (5’-GMP) showed unusual reactivity. Unlike most previously studied platinum triamine compounds, Me5dien compound was reacting faster with 5’-GMP than N-AcMet, due to the bulkiness of the triamine ligand. When both N-AcMet and 5’-GMP were reacted with Et2dien, 5’- GMP displaced one amine group of the triamine ligand and replaced that spot to form a bis-adducts, when the pH was kept below 4. Here a new novel platinum compound has been synthesized with a seven-membered chelate ring triamine ligand, Chloro[2-(4- methyl-1,4-diazepan-1-yl)ethanamine]platinum(II) chloride ([Pt(L)Cl]+). The unusual binding activity of [Pt(L)Cl]+ showed a unique pair of products under 1H NMR, 195Pt NMR and LC/MS spectrometry.


Inorganic Chemicals | Inorganic Chemistry | Medicinal-Pharmaceutical Chemistry